Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart dise… Read more
Cardio Diagnostics Holdings Inc (CDIO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.171x
Based on the latest financial reports, Cardio Diagnostics Holdings Inc (CDIO) has a cash flow conversion efficiency ratio of -0.171x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.39 Million) by net assets ($8.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cardio Diagnostics Holdings Inc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Cardio Diagnostics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cardio Diagnostics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cardio Diagnostics Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CytoMed Therapeutics Limited Ordinary Shares
NASDAQ:GDTC
|
-0.205x |
|
Saigon Garment Manufacturing Trade JSC
VN:GMC
|
N/A |
|
Venari Minerals NL
AU:VMS
|
-0.021x |
|
Group 6 Metals Ltd
AU:G6M
|
0.200x |
|
Activeport Group Ltd
AU:ATV
|
-0.155x |
|
Bumi Citra Permai Tbk
JK:BCIP
|
0.024x |
|
MAA Group Bhd
KLSE:1198
|
-0.035x |
|
Planet Communications Asia Public Company Limited
BK:PLANET
|
0.056x |
Annual Cash Flow Conversion Efficiency for Cardio Diagnostics Holdings Inc (2020–2024)
The table below shows the annual cash flow conversion efficiency of Cardio Diagnostics Holdings Inc from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.56 Million | $-4.99 Million | -0.522x | +72.76% |
| 2023-12-31 | $2.96 Million | $-5.67 Million | -1.917x | -62.02% |
| 2022-12-31 | $4.30 Million | $-5.09 Million | -1.183x | -115.97% |
| 2021-12-31 | $1.07 Million | $-585.29K | -0.548x | -227.92% |
| 2020-12-31 | $60.37K | $25.86K | 0.428x | -- |